Company news

Q32 Bio Inc. news in 2024

Q32 Bio Inc.'s news releases, calls and decks from 2024, newest first.

View company

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

December 9, 2024

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

November 4, 2024

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

October 13, 2024

Q32 Bio to Participate in Upcoming September Investor Conferences

August 28, 2024

Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 7, 2024

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

July 8, 2024

Q32 Bio Joins Russell 3000® Index

June 30, 2024

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

April 2, 2024

Homology Medicines Declares Distribution to Common Stockholders

March 17, 2024

Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

January 2, 2024

Decks in 2024